Allergic disorders, skin disorders, collagen diseases, connective tissue inflammation, and arthritis.

Hormones & Synthetic substitutes- Adrenals

1.For patients with peptic ulcers or a history of peptic ulcers, it is generally advisable to avoid use, or to administer it in combination with antacids and gastric mucosal protective agents. 2.The following conditions are contraindications for this class of drugs: psychosis, severe psychoneurosis, active peptic ulcer, and infections that do not respond to antibiotics.

Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; however, information is conflicting and may be influenced by maternal dose, duration/frequency of exposure, and indication for use. Additional data are needed to evaluate any potential risk of systemic corticosteroids and other adverse pregnancy outcomes

Triamcinolone may be present in breast milk (may be dose dependent).

1.Common adverse reactions:Pain and swelling at the injection site, subcutaneous fat atrophy, skin thinning or discoloration, and facial flushing. 2.Rare adverse reactions:Moon face, insomnia, hirsutism, acne, osteoporosis, etc.

For intramuscular injection: 20–80 mg per dose, with adjustments made as appropriate according to symptoms. This medication is restricted to use by physicians only.

Juvenile idiopathic arthritis (JIA), other rheumatic conditions: Triamcinolone acetonide (Kenalog-10, -40, or -80): Children and Adolescents: Intra-articular: Initial: Smaller joints: 2.5 to 5 mg, larger joints: 5 to 15 mg; maximum dose/treatment (several joints at one time): 20 to 80 mg. Canadian labeling: Triamcinolone hexacetonide (Canadian product; not available in the US): Children 3 to 12 years: Intra-articular: Large joints (knees, hips, shoulders): 1 mg/kg/dose. Small joints (ankles, wrists, elbows): 0.5 mg/kg/dose. Hands and feet: Metacarpophalangeal/metatarsophalangeal joints: 1 to 2 mg/dose. Proximal interphalangeal joints: 0.6 to 1 mg/dose. Adolescents: Intra-articular: Average dose: 2 to 20 mg/dose every 3 to 4 weeks as necessary; to avoid possible joint destruction use as infrequently as possible. Dose dependent upon degree of inflammation and joint involved: Large joints (knee, hip, shoulder): 10 to 20 mg/dose. Smaller joints (interphalangeal, metacarpophalangeal): 2 to 6 mg/dose.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Store at 15°C to 30°C